We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Disease Severity Predicted by Computer Model

By Biotechdaily staff writers
Posted on 25 Nov 2002
A study has shown that a computer model can be used to predict phenotypic behavior based on genetic information obtained from mapping of single nucleotide polymorphisms (SNPs). More...
The study was published in the November 2002 issue of Genome Research.

Single nucleotide polymorphisms are DNA sequence variations that occur when a single nucleotide (A,T,C,or G) in the genome sequence is changed. About two-thirds of all SNPs involve the replacement of cytosine (C) with thymine (T). SNPs occur every 100 to 300 bases along the human genome and are stable from an evolutionarily standpoint, making them easier to follow in population studies.

In the current study, researchers from the University of California, San Diego (UCSD, USA; www.ucsd.edu) used a computer model to relate specific genetic mutations to exact variations of a disease. They reviewed genetic information from patients who had an enzyme deficiency that caused hemolytic anemia. By inserting specific DNA sequences into a computer model for red blood cell metabolism, it was possible to predict accurately which mutations would result in chronic hemolytic anemia and which would cause a less severe version of the disease.

"The model is like the wiring diagram or design drawings for the cell,” explained senior author Dr. Bernhard Palsson, of the bioengineering department at UCSD. "It incorporates all the genes in the cell, the products of each, and the interwoven process of how those products interact to produce cellular functions. Once we have this computer model, it is in principle a fairly straightforward process to alter a specific DNA sequence, run a simulation on the program, and receive information back about how the defect impacts the cell's function.”

"Eventually, there could be a kind of databank of specific genetic mutations that cause precise disease variants,” said Dr. Palsson. "Some mutations will be severe, others benign. And every variation of a disease could be treated differently. This could be incredibly useful for drug development and will aid physicians in creating effective treatment plans for individuals.”



Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.